Stroke & IR

Getting your Trinity Audio player ready...
Insulin Resistance & Stroke — USA & UK 1975–2022

Insulin Resistance & Stroke

Prevalence trajectories in the USA and United Kingdom, 1975–2022. The link between insulin resistance and stroke is well-established and mechanistically direct: insulin resistance drives atherosclerosis, endothelial dysfunction, chronic inflammation, and hypertension — the four primary pathways to ischaemic stroke. Studies using HOMA-IR show that insulin resistance is an independent stroke risk factor even in people without diabetes. Critically, 50% of non-diabetic stroke and TIA patients show significant insulin resistance on testing — the very population conventional medicine currently overlooks.

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as that particular disease. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest this condition until their 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in this condition over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but many other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

United States

USA — Insulin Resistance vs Stroke

1975 – 2022  |  % of population
Insulin Resistance (%)
Stroke Prevalence (%)
United Kingdom

UK — Insulin Resistance vs Stroke

1975 – 2022  |  % of population
Insulin Resistance (%)
Stroke Prevalence (%)
r = 0.96
USA
IR ↔ Stroke
r = 0.95
UK
IR ↔ Stroke
50%
of non-diabetic stroke patients
show significant IR on testing
4.3Ă—
increased stroke risk
with low insulin sensitivity
Why the USA and UK percentages differ: The USA figure plots stroke prevalence as a percentage of all adults aged 18 and over, based on CDC BRFSS surveillance data (2.9% in 2020–2022, up from 1.41% in 1971–1975 per NHANES). The UK figure plots stroke and TIA survivors as a percentage of the total UK adult population using NHS and Stroke Association records (approximately 1.17% in 2022, from around 0.64% in 1975). The higher USA figure partly reflects broader self-report methodology and a larger absolute population with metabolic risk factors, but both series show the same directional upward trend in parallel with rising insulin resistance.
Four converging vascular pathways — all driven upstream by insulin resistance: (1) Atherosclerosis: hyperinsulinaemia promotes vascular smooth muscle cell proliferation and accelerates plaque formation in carotid and cerebral arteries — the primary anatomical mechanism for ischaemic stroke, which accounts for 87% of all strokes. (2) Endothelial dysfunction: insulin resistance impairs nitric oxide production, reducing vascular flexibility and promoting clot formation. (3) Chronic inflammation: insulin resistance elevates CRP and pro-inflammatory cytokines, independently associated with stroke recurrence and poor recovery outcomes. (4) Hypertension: insulin resistance directly promotes sodium retention and sympathetic nervous system activation, driving the raised blood pressure that is stroke's most cited risk factor. A prospective Northern Manhattan Study cohort (n=1,509 non-diabetic adults) confirmed HOMA-IR in the top quartile independently predicted first ischaemic stroke after adjusting for all conventional cardiovascular risk factors. The same integrated protocol addressing insulin resistance at root therefore addresses stroke risk through all four pathways simultaneously. Sources: Rundek et al. (Arch Neurol 2010); Frontiers Endocrinology (2022); PMC Cureus review (2023); NHANES 2024.
Data sources
Stroke USA — prevalence trend: NHANES I–III (1971–1994): stroke prevalence increased from 1.41% to 1.87% among adults aged 25–74 (Broderick et al., Stroke 2004). CDC BRFSS surveillance 2011–2022: overall age-standardised prevalence 2.7% (2011–2013) rising to 2.9% (2020–2022) with a 7.8% relative increase (MMWR May 2024). Pre-2000 interpolation based on NHANES cohort trend data. CDC Facts and Figures 2024: 795,000 strokes/year, 1 every 40 seconds.
https://www.cdc.gov/mmwr/volumes/73/wr/mm7320a1.htm
https://www.ahajournals.org/doi/10.1161/01.str.0000015031.57955.d1
https://www.cdc.gov/stroke/data-research/facts-stats/index.html
Stroke UK — prevalence trend: UK General Practice Research Database 1999–2008: stroke prevalence rose 12.5% from 6.4 to 7.2 per 1,000 persons (PMC3211058). Stroke Association UK 2024: approximately 1.3 million stroke survivors in the UK. Pre-2000 estimates from Rothwell et al. Oxford Vascular Study (Lancet 2004) and Stroke Association historical records. Age & Ageing projections (2020) for back-validation of 1975 estimates.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3211058/
https://www.stroke.org.uk/stroke/statistics
https://pmc.ncbi.nlm.nih.gov/articles/PMC7047821/
Insulin Resistance & Stroke — mechanistic and epidemiological evidence: Rundek T et al. — Insulin resistance and risk of ischemic stroke among nondiabetic individuals: Northern Manhattan Study (Arch Neurol 2010). Sojitra MH et al. — Exploring the Role of Insulin Resistance in Fueling Stroke Vulnerability (Cureus 2023, PMC10688238). Deng X et al. — Insulin resistance in ischemic stroke: mechanisms and therapeutic approaches (Frontiers Endocrinology 2022, PMC9798125). Hankey GJ — Insulin resistance: a possible causal and treatable risk factor for ischemic stroke (Arch Neurol 2010). Frontiers Neurology — METS-IR and stroke risk, NHANES 2007–2018 (2024).
https://pmc.ncbi.nlm.nih.gov/articles/PMC10688238/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9798125/
https://pubmed.ncbi.nlm.nih.gov/20937946/
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1478884/full
Insulin Resistance USA & UK: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); NHS Health Survey England; GBD 2019 metabolic risk; Diabetes UK; Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
Scroll to Top
MENU
For Radiant Health